Dr. Jack Cush talks of birthdays, Quizzes and journal articles this week on the podcast.
All News
UCB has released the Week 16 results from BE BOLD trial that will be presented at EULAR 2026 in London on Saturday, June 6.
Palindromic rheumatism may develop rheumatoid arthritis (RA) and could be an at-risk population. A pilot trial compared abatacept (ABA) versus hydroxychloroquine and demonstrated ABA reduces RA development in a 2 year study.
A current review of eosinophilic granulomatosis with polyangiitis (EGPA) provides current recommendations on diagnosis and management.
Toll-Like Receptor Drugs Effective in Cutaneous Lupus
Enpatoran, an investigational oral drug that inhibits Toll-like receptors (TLR) 7 and 8, was superior to placebo in relieving lupus skin manifestations in a dose-finding phase II trial.
For decades, the standard of care in rheumatology has been combination therapy - pairing methotrexate (MTX) with an advanced biologic or synthetic agent to achieve optimal outcomes.
